The DOI matches its Crossref record, with a small difference in title or year.
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis
Abstract
OBJECTIVE: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-acting intranasal therapy for depression and is currently under development for suicidality. The authors sought to determine the efficacy of adjunctive intranasal esketamine in major depressive disorder (MDD). DATA SOURCES: A systematic search of PubMed/MEDLINE was conducted up to January 2019, in addition to abstracts of major psychiatric meetings held since 2010. Searches were conducted by cross-referencing the term intranasal with the term esketamine. Where necessary, authors and/or study sponsors were contacted in order to obtain a copy of the presentation as well as any pertinent study details. STUDY SELECTION: 241 study abstracts were initially identified and reviewed. Selected studies were randomized, double-blind clinical trials comparing adjunctive intranasal esketamine to adjunctive placebo for MDD. DATA EXTRACTION: Data were extracted independently by two of the authors. A random effects model was used to calculate the standardized mean difference (SMD) between esketamine and placebo (intranasal saline) in the Montgomery-Asberg Depression Rating Scale (MADRS) score change from baseline to endpoint, serving as the primary outcome of the study. RESULTS: Five trials with 774 patients were pooled. Adjunctive esketamine was significantly more effective than placebo for MADRS score change, response, and remission (N = 774, SMD = 0.36, 95% CI = 0.24-0.49, P < .0001; response: risk ratio [RR] = 1.40, 95% CI = 1.22-1.61, P < .0001; remission: RR = 1.45, 95% CI = 1.20-1.75, P < .0001). Results remained statistically significant regardless of differences in the study sample, fixed vs new/optimized baseline antidepressants. CONCLUSIONS: Adjunctive intranasal esketamine for patients with MDD who are either treatment-resistant or acutely suicidal appears to be an effective treatment strategy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, uncertainty persists regarding (i) consistency of short-term efficacy across induction trials (including older adults), (ii) durability of benefit during maintenance and relapse prevention, (iii) comparative impact on functional outcomes, and (iv) the frequency and clinical relevance of key adverse events and discontinuations.”
In the citing paper
“Multiple evidence syntheses of esketamine have been published, generally indicating statistically significant symptom improvement versus placebo but raising questions about clinical magnitude, heterogeneity across trials and populations, and trade-offs in adverse events (26–28).”
In the citing paper
“Recent secondary evidence has likewise concluded that intranasal esketamine improves depressive symptoms and response outcomes in TRD while increasing acute adverse effects such as dizziness and nausea, which is consistent with our safety synthesis (26–28)”
Citations
Cites
Still being checked.
Cited by
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Taken together, results from meta-analyses suggest superiority of intravenous ketamine or esketamine when compared with second-generation antipsychotics (19, 143, 150, 151).”
BackgroundResultSelf-citationPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Self-citationWalsh, Z., Mollaahmetoglu, O. M., Rootman, J., Golsof, S., Keeler, J., Marsh, B., Nutt, D. J., & Morgan, C. J. A. (2022) · BJPsych Open · doi:10.1192/bjo.2021.1061 · Cited by 186
Depression: Biological markers and treatment
Erjavec, G. N., Šagud, M., Perković, M. N., Štrac, D. Š., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 136
Metadata
- Authors
- Papakostas, G. I., Salloum, N. C., Hock, R. S., Jha, M. K., Murrough, J. W., Mathew, S. J., Iosifescu, D. V., & Fava, M.
- Affiliations
- Harvard University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Michael E. DeBakey VA Medical Center (US)
- New York University (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2020-05-26
- Volume
- 81
- Issue
- 4
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W3029166129
- Cited by
- 108
- References
- 0
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 14 · 2023: 29 · 2022: 18 · 2021: 23 · 2020: 5
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, major depressive disorder, adjunctive therapy, intranasal administration, rapid-acting antidepressants, treatment-resistant depression, suicidal depression, remission, response, placebo comparison
- MeSH terms
- Administration, Intranasal, Antidepressive Agents, Major Depressive Disorder, Drug Therapy, Combination, Humans, Ketamine, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. https://app.cochat.ai/papers/10.4088/jcp.19r12889
- The paper
- Papakostas, G. I., Salloum, N. C., Hock, R. S., Jha, M. K., Murrough, J. W., Mathew, S. J., Iosifescu, D. V., & Fava, M. (2020). Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19r12889
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.